Topic

Soliris (eculizumab)

A collection of 51 issues

How to Get Soliris (Eculizumab) Covered by Humana in Texas: Complete Prior Authorization and Appeals Guide

Quick Answer: Soliris (eculizumab) requires prior authorization from Humana for all FDA-approved conditions (PNH, aHUS, myasthenia gravis, NMOSD). Key requirements: meningococcal vaccination ≥2 weeks before treatment, diagnostic confirmation, and step therapy documentation. Submit through CenterWell Specialty Pharmacy or fax to 877-486-2621. If denied, Texas residents have 65 days to appeal
5 min read

How to Get Soliris (eculizumab) Covered by Cigna in New Jersey: Complete Prior Authorization and Appeals Guide

Answer Box: Your Fastest Path to Soliris Coverage Cigna requires prior authorization for Soliris (eculizumab) with a 72-hour standard review (24 hours if expedited). Key requirements: confirmed diagnosis via flow cytometry (PNH) or antibody testing (gMG/NMOSD), meningococcal vaccinations ≥2 weeks before treatment, REMS enrollment, and documented prior therapy failures.
6 min read

Do You Qualify for Soliris (Eculizumab) Coverage by Cigna in Florida? Decision Tree & Next Steps

Answer Box: Soliris (Eculizumab) Coverage by Cigna in Florida Cigna requires prior authorization for Soliris (eculizumab) with 72-hour standard review (24 hours expedited). Key requirements: FDA-approved diagnosis confirmation, meningococcal vaccination ≥2 weeks before treatment, REMS enrollment, and prior therapy documentation. Submit via CoverMyMeds or provider portal. If denied, internal appeals
6 min read

How to Get Soliris (Eculizumab) Covered by Aetna CVS Health in Georgia: Complete Prior Authorization Guide

Quick Answer: Getting Soliris Covered by Aetna CVS Health in Georgia Aetna CVS Health requires prior authorization for Soliris (eculizumab) with diagnosis-specific criteria, mandatory meningococcal vaccination ≥2 weeks before treatment, and CVS Specialty Pharmacy dispensing. Submit the Soliris Precertification Form (GR-68742) via Availity portal or fax 1-844-268-7263. If denied, Georgia
5 min read

How to Get Soliris (Eculizumab) Covered by UnitedHealthcare in Virginia: Complete Forms, Appeals, and Contact Guide

Answer Box: Getting Soliris (Eculizumab) Covered by UnitedHealthcare in Virginia UnitedHealthcare requires prior authorization for Soliris (eculizumab) under the medical benefit (HCPCS J1299) with diagnosis-specific criteria including lab confirmation, failed prior therapies, and REMS compliance. Submit PA via UnitedHealthcare provider portal or fax to 1-844-403-1028. If denied, you have 180
7 min read

How to Get Soliris (Eculizumab) Covered by Humana in Georgia: Complete Coding, Authorization & Appeals Guide

Quick Answer: Getting Soliris (Eculizumab) Covered by Humana in Georgia Soliris (eculizumab) requires prior authorization from Humana for all FDA-approved conditions. The fastest path: ensure meningococcal vaccination ≥2 weeks prior, gather diagnostic labs (flow cytometry for PNH, AQP4-IgG for NMOSD), and submit through CenterWell Specialty Pharmacy with proper ICD-10 coding.
5 min read

How to Get Soliris (Eculizumab) Covered by Blue Cross Blue Shield of Michigan: Complete Guide with Forms, Timelines, and Appeal Scripts

Answer Box: Getting Soliris Covered by BCBS Michigan To get Soliris (eculizumab) covered by Blue Cross Blue Shield of Michigan, you'll need prior authorization through their NovoLogix system. Since July 2024, BCBS Michigan requires patients to try Empaveli (pegcetacoplan) first for most indications unless contraindicated. The fastest path:
7 min read

Renewing Soliris (Eculizumab) Coverage with Blue Cross Blue Shield in North Carolina: Complete Timeline and Documentation Guide

Answer Box: Soliris (eculizumab) requires annual reauthorization with Blue Cross Blue Shield of North Carolina. Start renewal 30-60 days before expiration by gathering updated labs (LDH, hemoglobin, platelets), clinical response documentation, and current vaccination records. Submit through Blue e or your specialty pharmacy. If denied, use Smart NC external review—
6 min read